Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise.
As of now, there are no specific treatments available for retinitis pigmentosa. Efficient treatments for retinitis pigmentosa are much awaited, particularly for genetically defined subsets of patients. Various studies suggest that this disease affects about 1 in 4,000 individuals worldwide. Without treatment, patients permanently lose central vision by the age of 60. For past many years, there have been several treatments reported, which did not completely cure the disease but were beneficial to some extent. For instance, in the past, patients used to consume a supplement of 15,000 I.U. of Vitamin A and possibly fish oil to address this conditions. In 2011, a method of treatment was patented, in which a medical dose of insulin, IGF-1, and chlorin e6 was used. Another treatment option which was proposed in November 2012 was a combined treatment regimen of oily fish (DHA), vitamin A palmitate, and lutein. This treatment was reported to slow vision loss in people suffering from the disease. Rare forms may also be treated with vitamin supplements or diet modification.
Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=91
Looking at the immense growth potential, several new players are likely to venture into the global retinitis pigmentosa market, thereby making it a highly competitive arena in the near future.
Global Retinitis Pigmentosa (RP) Market: Overview
Retinitis Pigmentosa (RP), an inherited retinal condition causing retinal degeneration and visual field loss, is a rare disease. Its initial symptoms are reduced night vision and loss of peripheral vision. It gradually causes blindness. There is no definitive cure for retinitis pigmentosa. Therefore, the market for treating this genetic disorder is vastly untapped. The available therapies apply various approaches such as stem cell therapy and transcorneal electric stimulation therapy. However, such therapies have not been approved of unanimously on account of certain intrinsic limitations.
A range of services and devices are available to aid people with vision loss to conduct their day to day activities independently. Those include anything from a vision aid and an eye care professional to orientation and mobility specialists and certified low vision therapists, among others.
Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=91
Global Retinitis Pigmentosa (RP) Market: Trends and Opportunities
The global retinitis pigmentosa market has been treading a healthy growth path due to limited availability of therapeutics to cure this rare disease which has opened up a window of opportunity for new therapies and treatments. In fact, most people afflicted with the genetic disorder progress to the advanced stage of retinitis pigmentosa because of the dearth of proper cure. This has generated demand for retinal prosthesis devices for restoring the lost vision. Second Sight Medical Products, Inc., for example, offers FDA approved Argus II retinal prosthesis system meant for patients with advanced retinitis pigmentosa. This device does the function of degenerated retinal cells and enhances the patient’s ability to see images and movement.
A new approach known as optogenetics, which involves applying gene therapy for restoring vision, is currently being researched upon by companies operating in the ophthalmology market. It helps to power cells, especially ganglion cells, to respond to light after the degeneration of rod cells and cone cells. Further, the orphan drug designation given by the FDA and European Commission to ReN003 by ReNeuron in the U.S. and Europe in 2013 is another positive development in the market. ReN003 is a retinal stem cell therapy candidate.
Read Comprehensive Overview of Report@ https://www.tmrresearch.com/retinitis-pigmentosa-market
Global Retinitis Pigmentosa (RP) Market: Regional Outlook
Based on geography, the global retinitis pigmentosa market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America and Europe dominate the market powered by the developed markets of the U.S and U.K. where exhaustive research and development activities have been carried out in this direction. However, the Asia Pacific market is also poised for growth due to the large patient pool in the region, who need to be treated for retinitis pigmentosa. The Rest of the World also has a substantial number of people suffering from this rare genetic disorder.
Companies Mentioned in Report
To present an study the current competitive dynamics in the global market for retinitis pigmentosa (RP), the report has profiled some of the major players involved in the development and commercialization of products in the field such as ReNeuron Group plc, Amarantus BioScience Holdings, Inc., Ocugen, Inc., ReGenX Biosciences, LLC, Sucampo Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Inc., and Okuvision GmbH.